Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Victor A ChowMazyar ShadmanAjay K GopalPublished in: Blood (2018)
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% to 40% of study-treated patients, but toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Keyphrases
- diffuse large b cell lymphoma
- cell therapy
- epstein barr virus
- drug administration
- clinical practice
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- palliative care
- prognostic factors
- electronic health record
- peritoneal dialysis
- randomized controlled trial
- machine learning
- acute lymphoblastic leukemia
- systematic review
- risk assessment
- patient reported outcomes
- climate change
- multiple myeloma
- nk cells
- replacement therapy